ITEM VIEW

Risk of pulmonary tuberculosis in children with congenital heart disease

dc.contributor.authorVan der Merwe P.-L.
dc.contributor.authorKalis N.
dc.contributor.authorSchaaf H.S.
dc.contributor.authorNel E.H.
dc.contributor.authorGie R.P.
dc.date.accessioned2011-05-15T16:17:36Z
dc.date.available2011-05-15T16:17:36Z
dc.date.issued1995
dc.identifier.citationPediatric Cardiology
dc.identifier.citation16
dc.identifier.citation4
dc.identifier.issn01720643
dc.identifier.urihttp://hdl.handle.net/10019.1/14287
dc.description.abstractChildren with low-flow congenital heart lesions are reported to have an increased incidence of pulmonary tuberculosis. The aim of this study was to investigate if children with congenital heart disease have an increased incidence of pulmonary tuberculosis and to determine if patients with certain heart conditions are more susceptible to pulmonary tuberculosis than others. This retrospective study over a 6-year period showed that pulmonary tuberculosis was 2.5 fold more common in children with congenital heart disease than in normal children from the same community. Children with congenital pulmonary stenosis had a prevalence equal to those with acyanotic (ventricular and atrial septal defects) and cyanotic (transposition of the great arteries) high flow heart lesions, whereas there were no cases of tuberculosis in children with low-flow cyanotic heart lesions such as tetralogy of Fallot. Cardiac surgery had to be postponed as a result of pulmonary tuberculosis in 7.2% of all patients in whom it was required. Over the 6-year period of the study, cardiac surgery had to be delayed in 60% of cases with pulmonary tuberculosis and congenital heart lesions so antituberculosis therapy could be completed. Physicians treating children with congenital heart lesions should maintain a high index of suspicion for the development of pulmonary tuberculosis, especially in those with acyanotic and cyanotic high flow lesions and pulmonary stenosis.
dc.subjectbcg vaccine
dc.subjectisoniazid
dc.subjectpyrazinamide
dc.subjectrifampicin
dc.subjecttuberculin
dc.subjecttuberculostatic agent
dc.subjectadolescent
dc.subjectarticle
dc.subjectchild
dc.subjectcongenital heart disease
dc.subjectfallot tetralogy
dc.subjectgreat vessels transposition
dc.subjectheart atrium septum defect
dc.subjectheart ventricle septum defect
dc.subjecthigh risk patient
dc.subjecthuman
dc.subjectincidence
dc.subjectinfant
dc.subjectlung blood flow
dc.subjectlung tuberculosis
dc.subjectmajor clinical study
dc.subjectnewborn
dc.subjectpulmonary valve stenosis
dc.subjecttuberculin test
dc.subjectAdolescent
dc.subjectAntitubercular Agents
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectHeart Defects, Congenital
dc.subjectHuman
dc.subjectIncidence
dc.subjectInfant
dc.subjectRetrospective Studies
dc.subjectRisk Factors
dc.subjectSouth Africa
dc.subjectSurvival Rate
dc.subjectTuberculin Test
dc.subjectTuberculosis
dc.titleRisk of pulmonary tuberculosis in children with congenital heart disease
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW